<DOC>
	<DOCNO>NCT01641796</DOCNO>
	<brief_summary>This expand access treatment protocol design provide topical cream treatment option military health care beneficiary parasitologically confirm uncomplicated Cutaneous Leishmaniasis .</brief_summary>
	<brief_title>Paromomycin Individuals With Uncomplicated Cutaneous Leishmaniasis</brief_title>
	<detailed_description>When military health care beneficiary present Department Defense Military Treatment Facility skin lesion clinically epidemiologically consistent suspicious Cutaneous Leishmaniasis ( CL ) , routine diagnostic parasitology test perform standard care , positive diagnosis , patient offer option participate treatment program provide write informed consent/assent. , eligible participate , patient receive treatment Paromomycin Topical Cream . Eligible patient receive Paromomycin Topical Cream apply topically CL lesion daily 20 day . The Day 1 application perform supervision site PI . The Day 2 application perform patient observed site PI designate medical staff member . The patient schedule return Medical Treatment Facility ( MTF ) weekly treatment Days 7 ± 2 , 14 ± 2 , Day 20 + 4 day ( last day treatment ) . During visit , member medical team observe application cream patient assist patient , necessary . In addition , patient schedule return safety evaluation approximately 1 week complete treatment . The patient instruct contact site PI designee unusual adverse event ( AEs ) occur treatment week complete treatment . The patient schedule return MTF Day 90 ( ± 14 day ) day start treatment determine whether CL lesion heal ( per CL standard care ) . Those patient return MTF contact phone . If time complete treatment lesion get bad appear infect , patient instruct go MTF possible treatment AEs alternative treatment CL .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Male female military health care beneficiary age . Diagnosis uncomplicated CL least one lesion parasitologically confirm least one follow method : 1 ) positive culture promastigotes ; 2 ) microscopic identification amastigotes stain lesion tissue ; and/or 3 ) PCR assay perform either LDL , WRAIR Clinical Parasitology Service , CDC . Ability comprehend willingness sign inform consent give assent CL lesion location amenable topical treatment Patient willing forgo treatment CL treatment program Females childbearing potential must negative pregnancy test within 1 day start treatment agree use acceptable method birth control start treatment 2 week complete treatment Clinically significant concomitant disease would preclude patient complete treatment opinion treat physician . Clinical Evidence mucosal involvement Known allergy aminoglycosides Females pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cutaneous Leishmaniasis</keyword>
	<keyword>CL</keyword>
	<keyword>Lesion</keyword>
	<keyword>Topical</keyword>
	<keyword>Treatment</keyword>
	<keyword>Cream</keyword>
	<keyword>Expanded Access</keyword>
</DOC>